TerminatedNot Applicable

RxWell in Pediatric IBD for Disease Management and Transition Readiness

Stopped: PI left the institution

United States7 participantsStarted 2022-07-30

Plain-language summary

Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.

Who can participate

Age range16 Years – 25 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals ages 16-25 years with established IBD who are followed in the pediatric gastroenterology clinics at the UPMC Children's Hospital of Pittsburgh * Patient must be English speaking * Access to Smartphone * PHQ-4 score ≥ 5 and/or TRAQ score ≥ 60 Exclusion Criteria: * Developmental delay

What they're measuring

Change in anxiety severity over time

Timeframe: 6 months

Change in depression severity

Timeframe: 6 months

Trial details

NCT IDNCT05461014

SponsorUniversity of Pittsburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-08

View on ClinicalTrials.gov More Mental Health Issue trials